It has been found that imatinib could cause drug resistance via recruitment of EZH2 to the promoter region of the PTEN and then downregulates PTEN’s transcripts in leukemia patients [35]; moreover, cumulative evidences revealed that lncRNAs interacted with EZH2 and recruited it to genes’ promoter regions to repress genes’ expression [36–38]. The gene discussed is EZH2; the disease is leukemia.